Q4 2024 Earnings Call Transcript March 20, 2025 TELA Bio, Inc. beats earnings expectations. Reported EPS is $-0.23, ...

Because LiquiFix is indicated for use only with synthetic mesh, we’ve been able ... engaging discussion on paraesophageal hernia repairs. Our long-term ventral and inguinal data were also ...

In a research article published in JAMA Surgery, Brian Fry, M.D., M.S., a general surgery resident at University of Michigan Health and colleagues compared hernia recurrence rates after undergoing ...

For example, in a study comparing suture repair of incisional hernia to mesh repair, it was found that "mesh repair results in a lower recurrence rate and less abdominal pain and does not result ...

The de novo submission is projected for late 2026. These milestones are crucial as the company targets the ventral hernia repair market and explores expansion into other soft tissue procedures.

We are incredibly excited about the potential of our first-generation platform not only to make a meaningful impact in our initial target indication of ventral hernia repair, but also across a ...

The global hernia mesh devices market was valued at USD 4.6 billion in 2022 and is expected to reach USD 6.5 billion by 2032, reflecting a Compound Annual Growth Rate (CAGR) of 3.4%. Inguinal hernias ...